Corbus Pharmaceuticals Holding Cash Flow Conversion Efficiency
Corbus Pharmaceuticals Holding cash flow conversion efficiency. Based on the latest financial reports, Corbus Pharmaceuticals Holding (CRBP) has a cash flow conversion efficiency ratio of -0.290x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.63 Million) by net assets ($102.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Corbus Pharmaceuticals Holding (2012–2025)
Cash flow conversion efficiency of Corbus Pharmaceuticals Holding from 2012 to 2025. This chart illustrates how Corbus Pharmaceuticals Holding's cash flow conversion efficiency has evolved over time, based on yearly financial data. View CRBP share price today for real-time trading data and today's change.
Corbus Pharmaceuticals Holding Cash Flow Conversion Ratio Explained
Corbus Pharmaceuticals Holding cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Corbus Pharmaceuticals Holding Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corbus Pharmaceuticals Holding ranked by their cash flow conversion efficiency. Also see CRBP company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
High Co. SA
PA:HCO
|
0.198x |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
0.065x |
|
Bibica Corp
VN:BBC
|
0.032x |
|
International Media Acquisition Corp
NASDAQ:IMAQ
|
0.006x |
|
Sheh Fung Screws Co Ltd
TWO:2065
|
0.021x |
|
Hwa Sung Ind
KO:002460
|
-0.010x |
|
Powertech Industrial Co Ltd
TW:3296
|
-0.016x |
|
Avgol Industries 1953 Ltd
TA:AVGL
|
0.050x |
Annual Cash Flow Conversion Efficiency for Corbus Pharmaceuticals Holding (2012–2025)
The table below shows the annual cash flow conversion efficiency of Corbus Pharmaceuticals Holding from 2012 to 2025. Review CRBP cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $147.50 Million | $-64.49 Million | -0.437x | -49.00% |
| 2024-12-31 | $142.43 Million | $-41.79 Million | -0.293x | -100.01% |
| 2023-12-31 | $-6.91 Million | $-36.10 Billion | 5228.164x | +459494.91% |
| 2022-12-31 | $32.99 Million | $-37.54 Million | -1.138x | -63.23% |
| 2021-12-31 | $69.11 Million | $-48.18 Million | -0.697x | +68.33% |
| 2020-12-31 | $45.27 Million | $-99.69 Million | -2.202x | +70.35% |
| 2019-12-31 | $6.16 Million | $-45.72 Million | -7.425x | -579.71% |
| 2018-12-31 | $27.52 Million | $-30.07 Million | -1.092x | -127.09% |
| 2017-12-31 | $57.78 Million | $-27.80 Million | -0.481x | +68.38% |
| 2016-12-31 | $8.92 Million | $-13.57 Million | -1.522x | -194.17% |
| 2015-12-31 | $8.99 Million | $-4.65 Million | -0.517x | -28.43% |
| 2014-12-31 | $5.86 Million | $-2.36 Million | -0.403x | -295.84% |
| 2013-12-31 | $-1.78 Million | $-366.71K | 0.206x | -94.70% |
| 2012-12-31 | $-198.38 | $-769.73 | 3.880x | -- |
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treat… Read more